CLGN - יחס מחיר להכנסות חזויות CollPlant Ltd

The primary driver for CollPlant Biotechnologies (CLGN) is its monopoly right to rhCollagen produced in tobacco. The forward P/S trend on the GURU.Markets terminal chart confirms this, where the 27.20 mark serves as the current indicator. Revenues are based on the supply of biomaterials for organ 3D printing and cosmetology. High B2B confidence from global corporations in the company's regenerative technologies opens significant growth prospects.

CollPlant Biotechnologies leads the regenerative medicine segment by creating innovative bio-inks from plant-based collagen. The company's forward P/S trend reflects the market value of the business relative to expected revenue, allowing investors to assess the asset's degree of overheating or its growth potential based on current sales forecasts and current share prices.